Leerink Partnrs Brokers Decrease Earnings Estimates for BPMC

Blueprint Medicines Co. (NASDAQ:BPMC) – Investment analysts at Leerink Partnrs cut their FY2026 earnings per share estimates for Blueprint Medicines in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings per share of $2.51 for the year, down from their previous estimate of $2.59. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Blueprint Medicines’ FY2027 earnings at $4.81 EPS.

A number of other analysts have also recently commented on the company. Wells Fargo & Company cut their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. JMP Securities restated a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research report on Wednesday, January 15th. HC Wainwright restated a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. JPMorgan Chase & Co. boosted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.72.

Blueprint Medicines Stock Down 4.2 %

Blueprint Medicines stock opened at $104.98 on Friday. The stock has a market capitalization of $6.67 billion, a PE ratio of -49.75 and a beta of 0.61. Blueprint Medicines has a 12 month low of $72.24 and a 12 month high of $121.90. The business has a 50 day simple moving average of $99.28 and a 200-day simple moving average of $95.14. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Insiders Place Their Bets

In other news, Director Jeffrey W. Albers sold 15,000 shares of the company’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total value of $1,346,550.00. Following the transaction, the director now owns 157,557 shares of the company’s stock, valued at $14,143,891.89. This represents a 8.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ariel Hurley sold 1,819 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the transaction, the insider now directly owns 14,967 shares in the company, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,851 shares of company stock valued at $4,984,696. Insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently modified their holdings of the company. Wealthfront Advisers LLC purchased a new stake in shares of Blueprint Medicines in the 4th quarter valued at $10,102,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Blueprint Medicines by 17.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,936 shares of the biotechnology company’s stock valued at $1,390,000 after buying an additional 2,323 shares during the period. Essex Investment Management Co. LLC raised its holdings in shares of Blueprint Medicines by 29.0% in the 4th quarter. Essex Investment Management Co. LLC now owns 45,736 shares of the biotechnology company’s stock valued at $3,989,000 after buying an additional 10,275 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Blueprint Medicines by 31.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,650 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 399 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Blueprint Medicines in the 4th quarter valued at $21,104,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.